Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Chem Biol Drug Des. 2016 Jan 17;87(5):794–805. doi: 10.1111/cbdd.12713

Figure 6.

Figure 6

Characterization of AQP1 inhibitors using vesicular assay. The plots represent swelling of NLS-treated AQP1-enriched erythrocyte ghosts under hypo-osmotic shock. Control is ghost only, without any compound. Inset shows a shrinkage assay for purified AQP1 reconstituted proteoliposomes exposed to hyper-osmotic shock. Control is AQP1 proteoliposome only, without any compound. In both sets of experiments, the compounds were at final concentration of 75 μM while HgCl2 was at a concentration of 50 μM.